Hersey, Peter
The University of Sydney · Melanoma Institute Australia · Icelandic Cancer Society
20 papers on CoChatORCID 0000-0002-3064-737X
Most cited papers
- Verified
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity
Cancer Immunotherapy and BiomarkersImmune cells in cancer
Cited by 5,870
- Verified
The repertoire of mutational signatures in human cancer
Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., Boot, A., Covington, K. R., Gordenin, D. A., Bergstrom, E. N., et al. (2020) · Nature
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 3,496
- Verified
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell
Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management
Cited by 3,151
- Verified
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 3,064
- Verified
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGenomics and Rare Diseases
Cited by 2,256
- Verified
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell
Cancer Cells and MetastasisPluripotent Stem Cells Research
Cited by 2,180
- Verified
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine
Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management
Cited by 2,156
- Verified
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 1,069
- Verified
The evolutionary history of 2,658 cancers
Gerstung, M., Jolly, C., Leshchiner, I., Dentro, S. C., Gonzalez, S., Rosebrock, D., Mitchell, T. J., Rubanova, Y., Anur, P., Yu, K., et al. (2020) · Nature
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 1,057
- Verified
Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images
Saltz, J., Gupta, R., Hou, L., Kurc, T., Singh, P., Nguyen, V., Samaras, D., Shroyer, K. R., Zhao, T., Batiste, R., et al. (2018) · Cell Reports
AI in cancer detectionCancer Immunotherapy and Biomarkers
Cited by 1,027
- Verified
Patterns of somatic structural variation in human cancer genomes
Li, Y., Roberts, N. D., Wala, J. A., Shapira, O., Schumacher, S. E., Kumar, K., Khurana, E., Waszak, S., Korbel, J. O., Haber, J. E., et al. (2020) · Nature
Cancer Genomics and DiagnosticsGenomic variations and chromosomal abnormalities
Cited by 867
- Verified
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
Cortés-Ciriano, I., Lee, J. J.-K., Xi, R., Jain, D., Jung, Y. L., Yang, L., Gordenin, D., Klimczak, L. J., Zhang, C.-Z., Pellman, D. S., et al. (2020) · Nature Genetics
Cancer Genomics and DiagnosticsGenomic variations and chromosomal abnormalities
Cited by 712
- Verified
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 665
- Verified
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 552
- Verified
Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition
Rodriguez-Martin, B., Alvarez, E. G., Baez-Ortega, A., Zamora, J., Supek, F., Demeulemeester, J., Santamarina, M., Ju, Y. S., Temes, J., Garcia-Souto, D., et al. (2020) · Nature Genetics
Genomic variations and chromosomal abnormalitiesCancer Genomics and Diagnostics
Cited by 451
- Verified
Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma
Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., Thompson, J. F., & Hersey, P. (2007) · Modern Pathology
Cutaneous Melanoma Detection and ManagementCell death mechanisms and regulation
Cited by 202
- Verified
Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells
Gray, C. P., Arosio, P., & Hersey, P. (2002) · Blood
Immunotherapy and Immune ResponsesT-cell and B-cell Immunology
Cited by 118
- Verified
Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production
Gray, C. P., Franco, A. V., Arosio, P., & Hersey, P. (2001) · International Journal of Cancer
Immune cells in cancerImmunotherapy and Immune Responses
Cited by 70
- Verified
Results of a multicenter, randomized, double‐blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Eisen, T., Trefzer, U., Hamilton, A., Hersey, P., Millward, M., Knight, R. D., Jungnelius, J. U., & Glaspy, J. (2010) · Cancer
Cutaneous Melanoma Detection and ManagementMelanoma and MAPK Pathways
Cited by 50
- Verified
Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
Pirozyan, M. R., McGuire, H. M., Emran, A. A., Tseng, H.-Y., Tiffen, J. C., Lee, J. H., Carlino, M. S., Menzies, A. M., Long, G. V., Scolyer, R. A., et al. (2020) · Frontiers in Immunology
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 34
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free